These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25372260)

  • 1. Asymptomatic annular plaques on the neck.
    Chabra IS; Grandinetti LM
    Cutis; 2014 Oct; 94(4):E1-3. PubMed ID: 25372260
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
    Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annular keratotic papules on the extremities.
    Bennett JA; Clarke JT; Ioffreda MD
    J Am Acad Dermatol; 2015 Nov; 73(5):891-3. PubMed ID: 26475551
    [No Abstract]   [Full Text] [Related]  

  • 4. [A case of myasthenia gravis caused by D-penicillamine therapy].
    Susa S; Akiba J; Kurimura M; Kurita K; Daimon M; Manaka H; Yamatani K; Kato T
    Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2513-5. PubMed ID: 9922674
    [No Abstract]   [Full Text] [Related]  

  • 5. Transient acantholytic dermatosis (Grover's disease) in a patient with progressive systemic sclerosis treated with D-penicillamine.
    Zvulunov A; Grunwald MH; Avinoach I; Halevy S
    Int J Dermatol; 1997 Jun; 36(6):476-7. PubMed ID: 9248901
    [No Abstract]   [Full Text] [Related]  

  • 6. Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis.
    Shapiro M; Jimenez S; Werth VP
    J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):297-9. PubMed ID: 10642693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary involvement in systemic sclerosis due to therapy and as a complication.
    Chiappini F; Zoli A; Maugeri L
    Monaldi Arch Chest Dis; 2005 Jun; 63(2):111-3. PubMed ID: 16128227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature.
    Derk CT; Jimenez SA
    J Rheumatol; 2003 Jul; 30(7):1616-20. PubMed ID: 12858467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of systemic sclerosis with D-penicillamine. A new method of observing the effects of treatment.
    Bluestone R; Grahame R; Holloway V; Holt PJ
    Ann Rheum Dis; 1970 Mar; 29(2):153-8. PubMed ID: 5427411
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythematous plaques on the flexural surfaces.
    Davis DM; Otley CC; Witman PM
    Arch Dermatol; 2005 Nov; 141(11):1457-62. PubMed ID: 16301396
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adverse reactions of immunomodulatory agents].
    Yamanaka H; Kashiwazaki S
    Ryumachi; 1990 Apr; 30(2):143-51. PubMed ID: 1978417
    [No Abstract]   [Full Text] [Related]  

  • 12. Postural changes, dysphagia, and systemic sclerosis.
    Barrera P; den Broeder AA; van den Hoogen FH; van Engelen BG; van de Putte LB
    Ann Rheum Dis; 1998 Jun; 57(6):331-8. PubMed ID: 9771206
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine.
    Katayama Y; Kohriyama K; Matsui T
    J Rheumatol; 1999 Nov; 26(11):2493-5. PubMed ID: 10555917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Obliterating bronchiolitis induced by D-penicillamine in the female patient with systemic scleroderma].
    Alekperov RT; Avdeev SN; Kotovskaia MA
    Ter Arkh; 2004; 76(3):74-6. PubMed ID: 15108466
    [No Abstract]   [Full Text] [Related]  

  • 15. [D-penicillamine-induced lipoid nephrosis in a patient with scleroderma].
    Kitazawa K; Ohseto Y; Kawazumi H; Saito K; Shibata T; Uchida J; Yonekura M; Shiwachi S; Ito S; Sugisaki T
    Ryumachi; 1982 Oct; 22(5):397-403. PubMed ID: 7157094
    [No Abstract]   [Full Text] [Related]  

  • 16. [D-penicillamine: an outdated cure for systemic scleroderma?].
    Marie I; Lévesque H; Courtois H
    Rev Med Interne; 1999 Dec; 20(12):1077-81. PubMed ID: 10635068
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experience using d-penicillamine in systemic scleroderma].
    Nemchinov EN; Krel' AA; Shekhter AB; Rashchupkina ZP
    Klin Med (Mosk); 1982 Jan; 60(1):77-82. PubMed ID: 7078046
    [No Abstract]   [Full Text] [Related]  

  • 18. [Allergic-toxic liver damage due to D-penicillamine].
    Rau R; Weber S; Böni A
    Schweiz Med Wochenschr; 1972 Aug; 102(34):1226-8. PubMed ID: 5055042
    [No Abstract]   [Full Text] [Related]  

  • 19. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus.
    Nagao K; Tanikawa A; Yamamoto N; Amagai M
    Clin Exp Dermatol; 2005 Jan; 30(1):43-5. PubMed ID: 15663502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
    Clements PJ; Seibold JR; Furst DE; Mayes M; White B; Wigley F; Weisman MD; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Wong WK
    Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.